Coherus BioSciences, Inc.

Coherus BioSciences is a commercial-stage biopharmaceutical company that has strategically transformed into a pure-play 'innovative oncology' firm. Originally known for its leadership in the biosimilar market, the company completed a major pivot in 2024-2025 by divesting its biosimilar franchises (UDENYCA, CIMERLI, and YUSIMRY) to focus exclusively on its proprietary immuno-oncology pipeline. The company's cornerstone asset is LOQTORZI (toripalimab), the first FDA-approved treatment for nasopharyngeal carcinoma (NPC). Coherus is now focused on developing synergistic combinations of LOQTORZI with its internal pipeline of novel antibodies targeting the tumor microenvironment, including IL-27 and CCR8 antagonists, to address high unmet needs in solid tumors such as liver, lung, and head and neck cancers.